Review
Copyright ©The Author(s) 2016.
World J Gastroenterol. Nov 21, 2016; 22(43): 9488-9505
Published online Nov 21, 2016. doi: 10.3748/wjg.v22.i43.9488
Table 1 Principal retrospective studies of cardiovascular diseases mortality and morbidity risk in patients with nonalcoholic fatty liver disease (published in the past 10 years)
Ref.Study designStudy sizeDiagnosis of NAFLDFollow-up duration (yr)Adjusted clinical variablesMajor findings
Ekstedt et al[13]Retrospective; Hospital-based129Histological13.7Matched for gender, age and countryNASH subjects (not those with simple steatosis) had higher rates of all-cause, CVD and liver-related mortality than the general population
Stepanova et al[15]Retrospective; Population-based289Histological6.25No adjustments madeHigher risk of liver-related mortality in NASH than non-NASH. NAFLD and type II diabetes had the highest risk for overall and liver-related mortality
Ekstedt et al[14]Retrospective; Community-based229Histological26.4NAFLD patients had increased risk of death, with a high risk of death from CVD and liver-related disease
Fibrosis stage predicted all-cause, CVD and liver-related death
Rafiq et al[10]Retrospective; Hospital-based173Histological13No adjustments madeHigher liver-related mortality but no difference in overall mortality (NASH vs simple steatosis)
Soderberg et al[11]Retrospective; Hospital-based118Histological18Matched for gender, age and yearIncreased total mortality in NAFLD was predominantly CV-related compared with matched reference population
Dunn et al[16]Retrospective cohort2343Computed tomography5No significant association was found between NAFLD and risk of all-cause mortality and cause-specific
(CVD, cancer and liver) mortality and morbidity. NAFLD patients
(steatosis > 30% on imaging) averaged 8 yr younger than those without NAFLD